Last reviewed · How we verify

Avibactam sodium/Ceftazidime hydrate (avibactam-sodium-ceftazidime-hydrate)

Pfizer Inc. · preclinical active

Avibactam sodium/Ceftazidime hydrate (generic name: avibactam-sodium-ceftazidime-hydrate) is a drug developed by Pfizer Inc.. It is currently in preclinical development.

Avibactam sodium/ceftazidime hydrate (Zavicefta®) is a fixed-dose combination antibiotic developed by Pfizer that pairs a third-generation cephalosporin (ceftazidime) with a novel beta-lactamase inhibitor (avibactam) to combat multidrug-resistant gram-negative bacterial infections. The combination works by protecting ceftazidime from enzymatic degradation by beta-lactamases while simultaneously providing direct bactericidal activity, restoring efficacy against pathogens resistant to cephalosporins alone. Zavicefta is FDA-approved for complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired/ventilator-associated bacterial pneumonia, with regulatory approvals across major markets including the EMA. The drug represents a significant advance in treating carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa, addressing a critical unmet need in serious gram-negative infections where resistance mechanisms have rendered traditional beta-lactams ineffective. Commercial uptake has been substantial, with peak annual sales exceeding $500 million globally, driven by high-acuity hospital use and the growing prevalence of multidrug-resistant pathogens. Pfizer continues to expand the clinical profile through additional indications and formulation development, including pediatric studies and sepsis-focused trials.

At a glance

Generic nameavibactam-sodium-ceftazidime-hydrate
SponsorPfizer Inc.
Phasepreclinical

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Avibactam sodium/Ceftazidime hydrate

What is Avibactam sodium/Ceftazidime hydrate?

Avibactam sodium/Ceftazidime hydrate (avibactam-sodium-ceftazidime-hydrate) is a pharmaceutical drug developed by Pfizer Inc..

Who makes Avibactam sodium/Ceftazidime hydrate?

Avibactam sodium/Ceftazidime hydrate is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of Avibactam sodium/Ceftazidime hydrate?

avibactam-sodium-ceftazidime-hydrate is the generic (nonproprietary) name of Avibactam sodium/Ceftazidime hydrate.

What development phase is Avibactam sodium/Ceftazidime hydrate in?

Avibactam sodium/Ceftazidime hydrate is in preclinical.

Related